157 related articles for article (PubMed ID: 22591013)
1. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma.
Atamaniuk J; Gleiss A; Porpaczy E; Kainz B; Grunt TW; Raderer M; Hilgarth B; Drach J; Ludwig H; Gisslinger H; Jaeger U; Gaiger A
Eur J Clin Invest; 2012 Sep; 42(9):953-60. PubMed ID: 22591013
[TBL] [Abstract][Full Text] [Related]
2. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
3. GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells.
Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A
Hematology; 2013 Nov; 18(6):348-51. PubMed ID: 23510526
[TBL] [Abstract][Full Text] [Related]
4. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
[TBL] [Abstract][Full Text] [Related]
5. [Expression and clinical significance of vascular endothelial growth factor and its receptors in multiple myeloma].
Liu JR; Luo SK; Li J; Su C
Ai Zheng; 2007 Jun; 26(6):652-6. PubMed ID: 17562275
[TBL] [Abstract][Full Text] [Related]
6. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
[TBL] [Abstract][Full Text] [Related]
7. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
8. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
[TBL] [Abstract][Full Text] [Related]
9. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections.
Specht K; Kremer M; Müller U; Dirnhofer S; Rosemann M; Höfler H; Quintanilla-Martinez L; Fend F
Clin Cancer Res; 2002 Sep; 8(9):2902-11. PubMed ID: 12231535
[TBL] [Abstract][Full Text] [Related]
10. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
11. Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma.
Andrade VC; Vettore AL; Regis Silva MR; Felix RS; Almeida MS; de Carvalho F; Zago MA; Caballero OL; Simpson AJ; Colleoni GW
Exp Hematol; 2009 Apr; 37(4):446-9. PubMed ID: 19211183
[TBL] [Abstract][Full Text] [Related]
12. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
[TBL] [Abstract][Full Text] [Related]
13. Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma.
Filipits M; Pohl G; Stranzl T; Kaufmann H; Ackermann J; Gisslinger H; Greinix H; Chott A; Drach J
Clin Cancer Res; 2003 Feb; 9(2):820-6. PubMed ID: 12576455
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma.
Ghossein RA; Coit D; Brennan M; Zhang ZF; Wang Y; Bhattacharya S; Houghton A; Rosai J
Clin Cancer Res; 1998 Feb; 4(2):419-28. PubMed ID: 9516931
[TBL] [Abstract][Full Text] [Related]
15. Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer.
Hata K; Dhar DK; Watanabe Y; Nakai H; Hoshiai H
Eur J Cancer; 2007 Jun; 43(9):1452-9. PubMed ID: 17442564
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 positive multiple myeloma: predominance of the short, 3'UTR-deficient transcript is associated with high cyclin D1 mRNA levels in cases with t(11;14) translocation, but does not correlate with proliferation rate or genomic deletions.
Slotta-Huspenina J; Koch I; Richter M; Bink K; Kremer M; Specht K; Krugmann J; Quintanilla-Martinez L; Fend F
Leuk Res; 2008 Jan; 32(1):79-88. PubMed ID: 17629555
[TBL] [Abstract][Full Text] [Related]
17. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival.
Cetin M; Buyukberber S; Demir M; Sari I; Sari I; Deniz K; Eser B; Altuntas F; Camci C; Oztürk A; Turgut B; Vural O; Unal A
Am J Hematol; 2005 Nov; 80(3):169-73. PubMed ID: 16247750
[TBL] [Abstract][Full Text] [Related]
19. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
20. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
Fonseca R; Harrington D; Oken MM; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Blood EA; Rajkumar SV; Kay NE; Van Ness B; Greipp PR
Cancer Res; 2002 Feb; 62(3):715-20. PubMed ID: 11830525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]